Company
Mindset Pharma Inc
CNSX:MSET
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, covering multiple drug development programs.
65 stories · page 1 of 4
Mindset Pharma and PharmAla Biotech forge exclusive sales agreement
The company said that PharmAla will be the exclusive global reseller of Mindset’s pharmaceutical-grade psilocybin to licensed clinical researchers
Mindset Pharma presents data showing its psilocin prodrug is better tolerated than psilocybin
MSP-1014, Mindet’s prodrug, was shown in mouse and rat pharmacokinetics studies to be rapidly and completely metabolized to psilocin, particularly when taken orally
Mindset Pharma chooses pair of psychedelic drug candidates to move Family 2 program forward
“Our teams continue to advance our collaboration to bring this innovative therapeutic into first-in-human clinical development," said CEO James Lanthier
Mindset Pharma provides strategic intellectual property license to Cybin for preclinical psychedelic drug research
"Both our companies share the same ultimate goal of discovering and developing superior new psychedelic treatments to better meet the needs of patients," said Mindset CEO James Lanthier
Mindset Pharma to advance lead psychedelic drug candidate MSP-1014 into Phase 1 first-in-human trial
“Moving our lead drug candidate forward to human trials will contribute to Mindset’s goal of reaching patients suffering from mental health conditions who are waiting for new medicines with meaningful benefits," CEO James Lanthier said
Mindset Pharma files 16 national patent applications to protect family of novel next-generation psychedelics
The company's CEO James Lanthier said the filing of multiple international applications for Family 1 will offer protection for Mindset's drug candidates as it looked to move MSP-1014 into human clinical trials as early as 2023
Mindset Pharma expands IP portfolio with three non-tryptamine families of next-gen psychedelic compounds
The Canadian company said it is increasing its discovery pipeline with three additional “chemically distinct families of highly novel,” non-tryptamine drug candidate compounds
Mindset Pharma CEO spotlights firm’s intranasal formulation technology, robust IP portfolio and partnerships
“The initial Proof-of-Concept of our intranasal technology using 5-MeO-DMT showed promising results,” noted Mindset Pharma CEO James Lanthier
Mindset Pharma granted allowance for patent covering its short-duration novel psychedelic medications
"This notice of allowance reaffirms the strength of Mindset's IP position and facilitates our ongoing development of Family 2, a highly differentiated asset in our mission to help patients with unmet needs via the discovery of optimized psy